BRCA1 and breast cancer: Patients with deleterious mutations in either the BRCA1 or BRCA2 gene have a 50% to 80% lifetime risk of developing breast cancer and a 20% to 40% lifetime risk of developing ovarian cancer [1–4,7–10].